CTLA4 and melanoma: Interestingly, The FDA approved relatlimab and nivolumab in patients with previously untreated advanced melanoma in March 2002 which is the second combination approved in this setting after nivolumab plus ipilimumab, an anti-CTLA-4 monoclonal antibody.